Thursday 02 May 2024
Internal Reference Number: FOI_7304
Date Request Received: 12/07/2023 00:00:00
Date Request Replied To: 02/08/2023 00:00:00
This response was sent via: By Email
Request Summary: Incidence and treatment of Colorectal Cancer
Request Category: Companies
| Question Number 1: In the past 3 months, how many patients have been treated for colorectal cancer [CRC] with the following agents? • Aflibercept • Bevacizumab • Capecitabine • CAPIRI • CAPOX (XELOX) • Cetuximab in combination with FOLFIRI/FOLFOX • Cetuximab not in combination with FOLFIRI or FOLFOX • Irinotecan only • FOLFIRI • FOLFOX • Fluorouracil (5FU) only • Oxaliplatin only • Nivolumab • Panitumumab in combination with FOLFIRI/FOLFOX • Panitumumab not in combination with FOLFIRI or FOLFOX • Pembrolizumab • Raltitrexed • Ramucirumab • Regorafenib • Tegafur + Uracil • Any other systemic anti-cancer therapy • Palliative care only | |
| Answer To Question 1: • Aflibercept0 • Bevacizumab 0 • Capecitabine 5 • CAPIRI 0 • CAPOX (XELOX) 20 • Cetuximab in combination with FOLFIRI/FOLFOX 0 • Cetuximab not in combination with FOLFIRI or FOLFOX 0 • Irinotecan only 0 • FOLFIRI 6 • FOLFOX 7 • Fluorouracil (5FU) only 0 • Oxaliplatin only 0 • Nivolumab 0 • Panitumumab in combination with FOLFIRI/FOLFOX <5 • Panitumumab not in combination with FOLFIRI or FOLFOX 0 • Pembrolizumab <5 • Raltitrexed 0 • Ramucirumab 0 • Regorafenib <5 • Tegafur + Uracil 0 • Any other systemic anti-cancer therapy 5 • Palliative care only unable to answer | |
| To return to the list of all the FOI requests please click here |
Our staff at Salisbury District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
